JP2010501534A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501534A5
JP2010501534A5 JP2009525103A JP2009525103A JP2010501534A5 JP 2010501534 A5 JP2010501534 A5 JP 2010501534A5 JP 2009525103 A JP2009525103 A JP 2009525103A JP 2009525103 A JP2009525103 A JP 2009525103A JP 2010501534 A5 JP2010501534 A5 JP 2010501534A5
Authority
JP
Japan
Prior art keywords
pharmaceutical
condition
under
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009525103A
Other languages
English (en)
Japanese (ja)
Other versions
JP5534811B2 (ja
JP2010501534A (ja
Filing date
Publication date
Priority claimed from GB0616747A external-priority patent/GB0616747D0/en
Application filed filed Critical
Priority claimed from PCT/GB2007/003173 external-priority patent/WO2008023159A1/en
Publication of JP2010501534A publication Critical patent/JP2010501534A/ja
Publication of JP2010501534A5 publication Critical patent/JP2010501534A5/ja
Application granted granted Critical
Publication of JP5534811B2 publication Critical patent/JP5534811B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009525103A 2006-08-24 2007-08-21 増殖性疾患の治療に有用なモルホリノピリミジン誘導体 Expired - Fee Related JP5534811B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0616747.2 2006-08-24
GB0616747A GB0616747D0 (en) 2006-08-24 2006-08-24 Novel compounds
US94854407P 2007-07-09 2007-07-09
US60/948,544 2007-07-09
PCT/GB2007/003173 WO2008023159A1 (en) 2006-08-24 2007-08-21 Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders

Publications (3)

Publication Number Publication Date
JP2010501534A JP2010501534A (ja) 2010-01-21
JP2010501534A5 true JP2010501534A5 (OSRAM) 2011-09-29
JP5534811B2 JP5534811B2 (ja) 2014-07-02

Family

ID=38720451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525103A Expired - Fee Related JP5534811B2 (ja) 2006-08-24 2007-08-21 増殖性疾患の治療に有用なモルホリノピリミジン誘導体

Country Status (15)

Country Link
US (1) US7750003B2 (OSRAM)
EP (1) EP2057140B1 (OSRAM)
JP (1) JP5534811B2 (OSRAM)
KR (1) KR101435231B1 (OSRAM)
AR (1) AR062526A1 (OSRAM)
AU (1) AU2007287428B2 (OSRAM)
CA (1) CA2660758A1 (OSRAM)
CL (1) CL2007002446A1 (OSRAM)
CO (1) CO6150160A2 (OSRAM)
IL (1) IL196998A0 (OSRAM)
MX (1) MX2009002046A (OSRAM)
NO (1) NO20090631L (OSRAM)
PE (1) PE20081362A1 (OSRAM)
UY (1) UY30559A1 (OSRAM)
WO (1) WO2008023159A1 (OSRAM)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4903164A (en) 1988-12-08 1990-02-20 Texas Instruments Incorporated O-ring/back-up ring seal for high pressure transducers
JP2000516743A (ja) * 1996-09-04 2000-12-12 インタートラスト テクノロージーズ コーポレイション 信用インフラストラクチャストラクチャ支援システム、安全な電子交易、電子商取引、交易プロセス制御及び自動化のための方法及び技術、分散コンピューテーション及び権利管理
US7935715B2 (en) 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
KR101435231B1 (ko) 2006-08-24 2014-10-02 아스트라제네카 아베 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
BRPI0718515A2 (pt) 2006-09-25 2013-11-19 Boehringer Ingelheim Int Compostos que modulam o receptor cb2
CA2673652A1 (en) * 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives and methods of use
ES2381895T3 (es) * 2007-02-06 2012-06-01 Novartis Ag Inhibidores de PI 3-quinasa y métodos para su uso
WO2009007748A2 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
CA2692720A1 (en) * 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
WO2009061652A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
CA2715835C (en) 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
JP2011520884A (ja) * 2008-05-13 2011-07-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を変調するスルホン化合物
PT3216793T (pt) 2008-05-23 2019-05-30 Wyeth Llc Compostos de triazina como inibidores de pi3 quinase e mtor
AU2009260782B2 (en) 2008-06-19 2014-12-11 Millennium Pharmaceuticals, Inc. Thiophene or thiazole derivatives and their use as PI3K inhibitors
US8178568B2 (en) 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
AR073354A1 (es) * 2008-07-31 2010-11-03 Genentech Inc Compuestos de pirimidina, composiciones farmaceuticas y su uso en el tratamiento del cancer.
EP2342191B1 (en) 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
EP2346825A2 (en) 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
NZ591111A (en) 2008-09-25 2013-08-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the cb2 receptor
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
UY32351A (es) 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2012516329A (ja) 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ阻害剤としてのヘテロアリールおよびその使用
WO2010103094A1 (en) 2009-03-13 2010-09-16 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2010120996A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120998A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2010120991A1 (en) * 2009-04-17 2010-10-21 Wyeth Llc 5, 6, 7, 8-tetrahydropyrido[4,3-d]pyrimidine compounds, their use as mtor, pi3, and hsmg-1 kinase inhibitors, and their syntheses
JPWO2010125799A1 (ja) * 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8383615B2 (en) 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
BRPI1011993A2 (pt) 2009-06-17 2021-07-06 Vertex Pharmaceuticals Incorporated inibidores de replicação do vírus influenza, seu uso, método de preparação dos mesmos e compositção farmacêutica que os compreende
US20100331305A1 (en) * 2009-06-24 2010-12-30 Genentech, Inc. Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
EP2480544A1 (en) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
EP2762142A1 (en) 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
BR112012011188A2 (pt) 2009-11-12 2021-06-29 F.Hoffmann - La Roche Ag ''composto,composição farmacêutica e uso de um composto"
US8828990B2 (en) 2009-11-12 2014-09-09 Genentech, Inc. N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use
US9315491B2 (en) 2009-12-28 2016-04-19 Development Center For Biotechnology Pyrimidine compounds as mTOR and PI3K inhibitors
WO2011088015A1 (en) 2010-01-15 2011-07-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US9249129B2 (en) 2010-03-04 2016-02-02 Cellzome Limited Morpholino substituted urea derivatives as mTOR inhibitors
WO2011109324A1 (en) 2010-03-05 2011-09-09 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the cb2 receptor
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
SG187795A1 (en) 2010-08-11 2013-03-28 Millennium Pharm Inc Heteroaryls and uses thereof
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
PT3040333T (pt) 2010-10-01 2018-12-04 Novartis Ag Formas cristalinas de 5- (2,6-di-4-morfolinil-4- pirimidinilo) -4-trifluorometilpiridina-2-amina, um inibidor de pik3
MX2013004003A (es) 2010-10-13 2013-10-01 Millenium Pharmaceuticals Inc Heteroarilos y usos de los mismos.
WO2012058671A1 (en) 2010-10-31 2012-05-03 Endo Pharmaceuticals Inc. Substituted quinazoline and pyrido-pyrimidine derivatives
EP2694511A1 (en) 2011-04-04 2014-02-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
CN102887867B (zh) * 2011-07-21 2015-04-15 中国科学院上海药物研究所 一类三嗪类化合物、该化合物的制备方法及其用途
CN103842357A (zh) * 2011-07-26 2014-06-04 格吕伦塔尔有限公司 作为类香草素受体配体的被取代的、含有杂芳环吡唑的羧酰胺和脲衍生物
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
HRP20171389T1 (hr) * 2011-09-02 2017-11-03 Purdue Pharma Lp Pirimidini kao blokatori natrijevog kanala
US9175011B2 (en) 2011-09-21 2015-11-03 Cellzone Limited Morpholino substituted urea or carbamate derivatives as MTOR inhibitors
RU2609208C2 (ru) 2011-10-07 2017-01-31 Селлзоум Лимитед МОРФОЛИНО-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ БИЦИКЛИЧЕСКИХ ПИРИМИДИНМОЧЕВИНЫ ИЛИ КАРБАМАТА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR
MX2014013725A (es) 2012-05-23 2015-02-10 Hoffmann La Roche Composiciones y metodos para obtener y utilizar celulas del endodermo y hepatocitos.
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
PT3068776T (pt) 2013-11-13 2019-08-26 Vertex Pharma Inibidores da replicação de vírus da gripe
WO2015073481A1 (en) 2013-11-13 2015-05-21 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
WO2015179707A1 (en) * 2014-05-21 2015-11-26 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
MY194204A (en) 2014-08-04 2022-11-21 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3630116B1 (en) 2017-05-26 2024-05-01 The Board Of Regents Of The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
PL3651768T3 (pl) 2017-07-13 2024-09-02 Board Of Regents, The University Of Texas System Heterocykliczne inhibitory kinazy atr
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
US10894052B2 (en) 2018-03-16 2021-01-19 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of ATR kinase
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性の化合物
PE20230240A1 (es) 2019-12-20 2023-02-07 Nuevolution As Compuestos activos frente a receptores nucleares
WO2021198955A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
US11613532B2 (en) 2020-03-31 2023-03-28 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
JP3810017B2 (ja) * 2000-04-27 2006-08-16 アステラス製薬株式会社 縮合ヘテロアリール誘導体
ATE503743T1 (de) * 2000-04-27 2011-04-15 Astellas Pharma Inc Kondensierte heteroarylderivate
AU2790502A (en) * 2000-11-10 2002-05-21 Hoffmann La Roche Pyrimidine derivatives and their use as neuropeptide y receptor ligands
KR101052482B1 (ko) * 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용
WO2005000404A2 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB0415367D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415365D0 (en) * 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
WO2007084413A2 (en) 2004-07-14 2007-07-26 Ptc Therapeutics, Inc. Methods for treating hepatitis c
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2586870A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Il-12 modulatory compounds
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
TW200720256A (en) * 2005-05-13 2007-06-01 Synta Pharmaceuticals Corp IL-12 modulatory compounds
ES2473341T3 (es) 2005-05-20 2014-07-04 Methylgene Inc Inhibidores de la se�alizaci�n del receptor del VEGF y del receptor del HGF
DE102005024494A1 (de) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Verwendung von Cyanopyrimidinen
KR20080015475A (ko) 2005-07-01 2008-02-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 피리미딘-치환 벤즈이미다졸유도체
JPWO2007013691A1 (ja) 2005-07-29 2009-02-12 武田薬品工業株式会社 スピロ環化合物
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP4531027B2 (ja) 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
ZA200802685B (en) 2005-09-30 2009-10-28 Vertex Pharma Deazapurines useful as inhibitors of janus kinases
JP5597353B2 (ja) 2005-09-30 2014-10-01 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB2431156A (en) 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
CA2626375A1 (en) 2005-10-28 2007-05-03 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2007063868A1 (ja) 2005-11-29 2007-06-07 Toray Industries, Inc. アリールメチレンウレア誘導体及びその用途
GB0525080D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525083D0 (en) 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
KR20080083188A (ko) 2006-01-11 2008-09-16 아스트라제네카 아베 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20080110998A (ko) 2006-01-30 2008-12-22 엑셀리시스, 인코포레이티드 Ｊａｋ­２ 조절자로서 ４­아릴­２­아미노­피리미딘 또는 4­아릴­２­아미노알킬­피리미딘 및 이들을 포함하는 약제학적 조성물
WO2007105023A1 (en) 2006-03-15 2007-09-20 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
JP5243696B2 (ja) 2006-03-17 2013-07-24 田辺三菱製薬株式会社 ベンゼン誘導体
WO2007114323A1 (ja) 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
JP2009534400A (ja) 2006-04-19 2009-09-24 ノバルティス アクチエンゲゼルシャフト インダゾール化合物およびｃｄｃ７の阻害方法
JP5225076B2 (ja) 2006-04-27 2013-07-03 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体の医薬用途
GB0610909D0 (en) 2006-06-05 2006-07-12 Merck Sharp & Dohme Therapeutic treatment
US8222256B2 (en) 2006-07-05 2012-07-17 Exelixis, Inc. Methods of using IGFIR and ABL kinase modulators
KR101435231B1 (ko) 2006-08-24 2014-10-02 아스트라제네카 아베 증식성 질환의 치료에 유용한 모르폴리노 피리미딘 유도체
WO2008023180A1 (en) 2006-08-24 2008-02-28 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008125833A1 (en) 2007-04-12 2008-10-23 Piramed Limited Pharmaceutical compounds

Similar Documents

Publication Publication Date Title
JP2010501534A5 (OSRAM)
JP2009535462A5 (OSRAM)
JP2007269812A5 (OSRAM)
JP2009149903A5 (OSRAM)
JP2011518833A5 (OSRAM)
JP2009545527A5 (OSRAM)
JP2006526031A5 (OSRAM)
JP2010536766A5 (OSRAM)
JP2008506632A5 (OSRAM)
JP2007522220A5 (OSRAM)
JP2018024670A5 (OSRAM)
JP2009013167A5 (ja) 有機金属錯体、発光材料、発光素子、及び発光装置
JP2019194236A5 (OSRAM)
JP2009502793A5 (OSRAM)
JP2011527560A5 (OSRAM)
JP2021502388A5 (OSRAM)
JP2011134884A5 (OSRAM)
JP2013532130A5 (OSRAM)
JP2010500116A5 (OSRAM)
JP2012111758A5 (OSRAM)
JP2011510079A5 (OSRAM)
JP2011508438A5 (OSRAM)
JP2010529196A5 (OSRAM)
JP2009544651A5 (OSRAM)
JP2011519871A5 (OSRAM)